Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GlaxoSmithKline (GSK) has decided to withdraw all of its marketing authorization applications for Avodart (dutasteride), indicated for the reduction of the risk of prostate cancer.
Subscribe to our email newsletter
Avodart prevents the conversion of testosterone to dihydrotestosterone (DHT) in the body.
GSK said that it will withdraw applications from regulatory review where procedures are ongoing and, in the limited number of countries where dutasteride is already indicated for use in prostate cancer risk reduction.